Stocks · News reference
Daiichi Sankyo Co (OTC:DSNKY) lowers FY2026 GAAP EPS guidance from $0.91 to $0.87 vs $1.04 analyst estimate. Raises FY2026 sales outlook from $14.537 billion to $14.684 billion vs $13.370 billion estimate.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Daiichi Sankyo and AstraZeneca’s Enhertu is the first and only HER2 directed medicine to improve progression-free survival over global standard of care in a phase 3 trial in this settingData to be presented at an
Read original at benzingaApproval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall
Read original at benzingaDaiichi Sankyo Co (OTC:DSNKY) reported quarterly earnings of $0.24 per share. This is a 25 percent decrease over earnings of $0.32 per share from the same period last year. The company reported $3.606 billion in sales
Read original at benzinga